Home » Newsletters » BioWorld Science

BioWorld Science

April 26, 2004

View Archived Issues

R&D highlights from the 3rd Annual Global Biotech Forum for Investing & Partnering: Ecopia

Novel 5-HT1F agonists with improved bioavailability for migraine therapy

R&D highlights from the 3rd Annual Global Biotech Forum for Investing & Partnering: Generex

M-826 is neuroprotective in a rat malonate model of Huntington's disease

WIN-55212-2 decreases hyperalgesia and pronociceptive mediators in a rat model of neuropathic pain

Topical resveratrol inhibits cutaneous HSV lesion formation in hairless mice

R&D highlights from the 3rd Annual Global Biotech Forum for Investing & Partnering: Genopia

R&D highlights from the 3rd Annual Global Biotech Forum for Investing & Partnering: Hudson Health

GABA-A alpha5 receptor inverse agonists with potential as cognition-enhancing agents

Novel HCV polymerase inhibitors for chronic hepatitis C therapy

Effects of hepatic and renal impairment on the pharmacokinetics of telbivudine

Chiron patent covers bacterial meningitis vaccines

LB-80380 reported to reduce serum HBV DNA levels in hepatitis B patients

Two series of DHFR inhibitors/melanocortin receptor modulators for IBD and other uses

Good safety and pharmacokinetic profile of Albuferon-alpha in chronic hepatitis C patients

New dopamine D1/D5 antagonists with potential in obesity and CNS disorders

Novel post-Amadori AGE inhibitors prepared and tested at BioStratum

Entecavir reduces viral levels in HBV-infected patients unresponsive to lamivudine

New alpha7 nAChR agonists claimed by Memory Pharmaceuticals researchers

Phase II trial of INS-37217 Ophthalmic for rhegmatogenous retinal detachment

Phenoxodiol studied in new ovarian cancer trial

Dose ranging study for EP-1572 growth hormone secretagogue

Interim data from phase II clofarabine study in AML reveal complete responses

Japanese approval sought for Peg-Intron plus Rebetol for chronic hepatitis C

Apokyn approved for off episodes associated with Parkinson's

IND clearance for squalamine in neovascular diseases of the eye

Approvable letter for Concerta

SBIR grant supports efforts at Adenosine Therapeutics in type 2 diabetes

Enrollment under way in phase II trial of avanafil for erectile dysfunction

Improved efficacy reported for ezetimibe/simvastatin in adult patients with hypercholesterolemia

Health Canada clears multiple dose range finding study for trans-ISA-247

Aventis Boards recommend improved offer from Sanofi-Synthelabo to create Sanofi-Aventis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...